Dataset from A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis

The purpose of this study is to evaluate, in participants having achieved a state of
sustained remission, if the ixekizumab treatment groups are superior to the placebo group in
maintaining response during the randomized withdrawal-retreatment period in participants with
axial spondyloarthritis.

本研究旨在评估已达到持续缓解状态的轴性脊柱关节炎（axial spondyloarthritis）受试者中，依奇珠单抗（ixekizumab）治疗组在随机停药-再治疗周期内维持临床应答的效果是否优于安慰剂组。